Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03096080 · ClinicalTrials.gov registry record · Phase 1
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
A Phase 1 study, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03096080 is a Phase 1 study that has completed, run by Kadmon Corporation. The registered enrollment target is 10 participants.
The verdict
NCT03096080, a Phase 1 study, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.
Interventions
- DRUG Tesevatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-08-24 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03096080
The ClinicalTrials.gov registry entry for NCT03096080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tesevatinib is the first listed.
NCT03096080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03096080 about?
NCT03096080 is a clinical study titled "A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)". This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.
What is the current status of trial NCT03096080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-08-24. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03096080?
The interventions under investigation include: Tesevatinib (DRUG).
Who is sponsoring clinical trial NCT03096080?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.